<DOC>
	<DOCNO>NCT01074255</DOCNO>
	<brief_summary>This survey conduct prepare application material re-examination Pharmaceutical Affairs Laws Enforcement Regulation . Its aim reconfirm clinical usefulness EMEMD ( aprepitant ) collect safety information accord Re-examination Regulation New Drugs .</brief_summary>
	<brief_title>Re-examination Study EMEND ( Aprepitant ) ( MK-0869-184 )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Participants treat EMEND first time per EMEND label Contraindication EMEND</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Post-chemotherapy</keyword>
</DOC>